Seelos Therapeutics (NASDAQ:SEEL) Trading Down 8.3%

Shares of Seelos Therapeutics, Inc. (NASDAQ:SEELGet Rating) traded down 8.3% during mid-day trading on Tuesday . The stock traded as low as $1.08 and last traded at $1.11. 1,532,056 shares were traded during trading, an increase of 2% from the average session volume of 1,495,659 shares. The stock had previously closed at $1.21.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Seelos Therapeutics in a research note on Monday, June 6th.

Seelos Therapeutics Stock Performance

The firm has a 50-day moving average price of $1.04 and a 200 day moving average price of $0.85. The firm has a market capitalization of $116.70 million, a PE ratio of -1.50 and a beta of 2.29. The company has a quick ratio of 3.60, a current ratio of 3.60 and a debt-to-equity ratio of 0.45.

Seelos Therapeutics (NASDAQ:SEELGet Rating) last released its quarterly earnings results on Friday, August 5th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. Research analysts expect that Seelos Therapeutics, Inc. will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. AdvisorShares Investments LLC raised its stake in Seelos Therapeutics by 82.4% in the first quarter. AdvisorShares Investments LLC now owns 358,796 shares of the company’s stock valued at $301,000 after buying an additional 162,119 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Seelos Therapeutics by 36.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,934,564 shares of the company’s stock valued at $1,621,000 after buying an additional 517,523 shares in the last quarter. Citigroup Inc. raised its stake in Seelos Therapeutics by 113.3% in the first quarter. Citigroup Inc. now owns 53,533 shares of the company’s stock valued at $45,000 after buying an additional 28,431 shares in the last quarter. Vanguard Group Inc. raised its stake in Seelos Therapeutics by 9.8% in the first quarter. Vanguard Group Inc. now owns 5,650,988 shares of the company’s stock valued at $4,735,000 after buying an additional 504,505 shares in the last quarter. Finally, Penserra Capital Management LLC raised its stake in Seelos Therapeutics by 16.7% in the first quarter. Penserra Capital Management LLC now owns 373,497 shares of the company’s stock valued at $235,000 after buying an additional 53,429 shares in the last quarter. 29.57% of the stock is currently owned by hedge funds and other institutional investors.

Seelos Therapeutics Company Profile

(Get Rating)

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).

See Also

Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.